<DOC>
	<DOCNO>NCT00936468</DOCNO>
	<brief_summary>This study design determine optimal dose JVRS-100 ass safety , tolerability immunogenicity Fluzone® vaccine administer JVRS-100 adjuvant one three dose level compare Fluzone® vaccine administer alone , 472 adult age ≥65 year .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Fluzone® With Without JVRS-100 Elderly Subjects</brief_title>
	<detailed_description>Approximately 472 subject enrol study . The study population include elderly male female subject age ≥65 year live community ( include assist living environment ) fit moderately frail . One hundred subject ( approximately 25 treatment arm ) vaccinate , 14 day elapse safety parameter monitor Data Safety Monitoring Board ( DSMB ) , randomize remain 372 subject .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Be adult volunteer age ≥65 year Live community , independently assist living environment Be Class 15 , define CSHACFS If female , postmenopausal Will available duration trial ( 21day On Study Period ) FollowUp ( 4 9 month vaccination ) Be 'probably demented ' MiniCog test Provide inform consent Agree defer receipt vaccination novel H1N1 ( swine ) influenza completion Day 28 study procedure Known allergy egg component vaccine . History severe reaction kind conventional influenza vaccine Be Class 67 CSHACFS institutionalize ( e.g. , nurse home ) Requiring nurse homelevel equivalent care home within community assist living environment Chronic administration immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . Significant cardiovascular disease ( e.g. , NYHA class 3 4 congestive heart failure ; myocardial infarction within past 6 month ; unstable angina ; coronary angioplasty within past 6 month ; uncontrolled ventricular cardiac arrhythmia ) ; rest heart rate &gt; 100 ; A history chronic obstructive pulmonary disease history lung disease require chronic steroid treatment excess bioequivalent dose 10 mg prednisone daily ; combine history lung disease anemia . Evidence significant ( 10 pound ) unintentional weight loss last year . Changed residence become hospitalize last 6 month . Combined history depression anemia . Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine study . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Use investigational product within 60 day precede administration study vaccine , plan use study period . Seropositive HIV HCV positive HBsAg Body temperature &gt; 38.1°C ( 100.6°F ) acute illness within 3 day prior vaccination ( subject may reschedule ) History excessive alcohol consumption , drug abuse , significant psychiatric illness . Be 'probably demented ' MinCog test Need guardian assistance complete informed consent Has receive vaccination novel H1N1 ( swine ) influenza</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Elderly influenza vaccine</keyword>
</DOC>